207 related articles for article (PubMed ID: 31417564)
1. Carcinoembryonic Antigen (CEA)-Specific 4-1BB-Costimulation Induced by CEA-Targeted 4-1BB-Agonistic Trimerbodies.
Mikkelsen K; Harwood SL; Compte M; Merino N; Mølgaard K; Lykkemark S; Alvarez-Mendez A; Blanco FJ; Álvarez-Vallina L
Front Immunol; 2019; 10():1791. PubMed ID: 31417564
[TBL] [Abstract][Full Text] [Related]
2. A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity.
Compte M; Harwood SL; Muñoz IG; Navarro R; Zonca M; Perez-Chacon G; Erce-Llamazares A; Merino N; Tapia-Galisteo A; Cuesta AM; Mikkelsen K; Caleiras E; Nuñez-Prado N; Aznar MA; Lykkemark S; Martínez-Torrecuadrada J; Melero I; Blanco FJ; Bernardino de la Serna J; Zapata JM; Sanz L; Alvarez-Vallina L
Nat Commun; 2018 Nov; 9(1):4809. PubMed ID: 30442944
[TBL] [Abstract][Full Text] [Related]
3. Case Report: An EGFR-Targeted 4-1BB-agonistic Trimerbody Does Not Induce Hepatotoxicity in Transgenic Mice With Liver Expression of Human EGFR.
Compte M; Harwood SL; Martínez-Torrecuadrada J; Perez-Chacon G; González-García P; Tapia-Galisteo A; Van Bergen En Henegouwen PMP; Sánchez A; Fabregat I; Sanz L; Zapata JM; Alvarez-Vallina L
Front Immunol; 2020; 11():614363. PubMed ID: 33488625
[TBL] [Abstract][Full Text] [Related]
4. An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity.
Compte M; Harwood SL; Erce-Llamazares A; Tapia-Galisteo A; Romero E; Ferrer I; Garrido-Martin EM; Enguita AB; Ochoa MC; Blanco B; Oteo M; Merino N; Nehme-Álvarez D; Hangiu O; Domínguez-Alonso C; Zonca M; Ramírez-Fernández A; Blanco FJ; Morcillo MA; Muñoz IG; Melero I; Rodriguez-Peralto JL; Paz-Ares L; Sanz L; Alvarez-Vallina L
Clin Cancer Res; 2021 Jun; 27(11):3167-3177. PubMed ID: 33785484
[TBL] [Abstract][Full Text] [Related]
5. A novel Carcinoembryonic Antigen (CEA)-Targeted Trimeric Immunotoxin shows significantly enhanced Antitumor Activity in Human Colorectal Cancer Xenografts.
Lázaro-Gorines R; Ruiz-de-la-Herrán J; Navarro R; Sanz L; Álvarez-Vallina L; Martínez-Del-Pozo A; Gavilanes JG; Lacadena J
Sci Rep; 2019 Aug; 9(1):11680. PubMed ID: 31406218
[TBL] [Abstract][Full Text] [Related]
6. Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy.
Schrand B; Berezhnoy A; Brenneman R; Williams A; Levay A; Kong LY; Rao G; Zhou S; Heimberger AB; Gilboa E
Cancer Immunol Res; 2014 Sep; 2(9):867-77. PubMed ID: 24938283
[TBL] [Abstract][Full Text] [Related]
7. Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity.
Qi X; Li F; Wu Y; Cheng C; Han P; Wang J; Yang X
Nat Commun; 2019 May; 10(1):2141. PubMed ID: 31105267
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies.
Chester C; Sanmamed MF; Wang J; Melero I
Blood; 2018 Jan; 131(1):49-57. PubMed ID: 29118009
[TBL] [Abstract][Full Text] [Related]
9. A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity.
Cheng LS; Cheng YF; Liu WT; Shen A; Zhang D; Xu T; Yin W; Cheng M; Ma X; Wang F; Zhao Q; Zeng X; Zhang Y; Shen G
J Transl Med; 2022 Sep; 20(1):415. PubMed ID: 36076251
[TBL] [Abstract][Full Text] [Related]
10. The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy.
Claus C; Ferrara-Koller C; Klein C
MAbs; 2023; 15(1):2167189. PubMed ID: 36727218
[TBL] [Abstract][Full Text] [Related]
11. Immuno-PET Imaging and Pharmacokinetics of an Anti-CEA scFv-based Trimerbody and Its Monomeric Counterpart in Human Gastric Carcinoma-Bearing Mice.
Rios X; Compte M; Gómez-Vallejo V; Cossío U; Baz Z; Morcillo MÁ; Ramos-Cabrer P; Alvarez-Vallina L; Llop J
Mol Pharm; 2019 Mar; 16(3):1025-1035. PubMed ID: 30726099
[TBL] [Abstract][Full Text] [Related]
12. Intramolecular trimerization, a novel strategy for making multispecific antibodies with controlled orientation of the antigen binding domains.
Alvarez-Cienfuegos A; Nuñez-Prado N; Compte M; Cuesta AM; Blanco-Toribio A; Harwood SL; Villate M; Merino N; Bonet J; Navarro R; Muñoz-Briones C; Sørensen KM; Mølgaard K; Oliva B; Sanz L; Blanco FJ; Alvarez-Vallina L
Sci Rep; 2016 Jun; 6():28643. PubMed ID: 27345490
[TBL] [Abstract][Full Text] [Related]
13. Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.
Claus C; Ferrara C; Xu W; Sam J; Lang S; Uhlenbrock F; Albrecht R; Herter S; Schlenker R; Hüsser T; Diggelmann S; Challier J; Mössner E; Hosse RJ; Hofer T; Brünker P; Joseph C; Benz J; Ringler P; Stahlberg H; Lauer M; Perro M; Chen S; Küttel C; Bhavani Mohan PL; Nicolini V; Birk MC; Ongaro A; Prince C; Gianotti R; Dugan G; Whitlow CT; Solingapuram Sai KK; Caudell DL; Burgos-Rodriguez AG; Cline JM; Hettich M; Ceppi M; Giusti AM; Crameri F; Driessen W; Morcos PN; Freimoser-Grundschober A; Levitsky V; Amann M; Grau-Richards S; von Hirschheydt T; Tournaviti S; Mølhøj M; Fauti T; Heinzelmann-Schwarz V; Teichgräber V; Colombetti S; Bacac M; Zippelius A; Klein C; Umaña P
Sci Transl Med; 2019 Jun; 11(496):. PubMed ID: 31189721
[TBL] [Abstract][Full Text] [Related]
14. Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity.
Eskiocak U; Guzman W; Wolf B; Cummings C; Milling L; Wu HJ; Ophir M; Lambden C; Bakhru P; Gilmore DC; Ottinger S; Liu L; McConaughy WK; He SQ; Wang C; Leung CL; Lajoie J; Carson WF; Zizlsperger N; Schmidt MM; Anderson AC; Bobrowicz P; Schuetz TJ; Tighe R
JCI Insight; 2020 Mar; 5(5):. PubMed ID: 32161196
[TBL] [Abstract][Full Text] [Related]
15. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
16. The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies.
Nelson MH; Fritzell S; Miller R; Werchau D; Van Citters D; Nilsson A; Misher L; Ljung L; Bader R; Deronic A; Chunyk AG; Schultz L; Varas LA; Rose N; Håkansson M; Gross J; Furebring C; Pavlik P; Sundstedt A; Veitonmäki N; Ramos HJ; Säll A; Dahlman A; Bienvenue D; von Schantz L; McMahan CJ; Askmyr M; Hernandez-Hoyos G; Ellmark P
Mol Cancer Ther; 2023 Jan; 22(1):89-101. PubMed ID: 36343381
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and safety of LEAD-452, an EGFR-specific 4-1BB-agonistic trimerbody in non-human primates.
Navarro R; Frago S; Hangiu O; Erce-Llamazares A; Lázaro-Gorines R; Morcillo MA; Rodriguez-Peralto JL; Sanz L; Compte M; Alvarez-Vallina L
Toxicol Appl Pharmacol; 2024 Jun; 487():116961. PubMed ID: 38740095
[TBL] [Abstract][Full Text] [Related]
18. Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function.
Buchan SL; Dou L; Remer M; Booth SG; Dunn SN; Lai C; Semmrich M; Teige I; Mårtensson L; Penfold CA; Chan HTC; Willoughby JE; Mockridge CI; Dahal LN; Cleary KLS; James S; Rogel A; Kannisto P; Jernetz M; Williams EL; Healy E; Verbeek JS; Johnson PWM; Frendéus B; Cragg MS; Glennie MJ; Gray JC; Al-Shamkhani A; Beers SA
Immunity; 2018 Nov; 49(5):958-970.e7. PubMed ID: 30446386
[TBL] [Abstract][Full Text] [Related]
19. A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity.
Schabowsky RH; Elpek KG; Madireddi S; Sharma RK; Yolcu ES; Bandura-Morgan L; Miller R; MacLeod KJ; Mittler RS; Shirwan H
Vaccine; 2009 Dec; 28(2):512-22. PubMed ID: 19836479
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
